Low Concentrations of C5a Complement Receptor Antibodies Are Linked to Disease Activity and Relapse in Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis
暂无分享,去创建一个
M. Huber-Lang | M. Nitschke | G. Riemekasten | A. Müller | C. Karsten | P. Lamprecht | S. Schinke | A. Koch | S. Klapa | S. Pitann | H. Heidecke | W. Kähler | A. Kerstein-Staehle | Solveig Augustin
[1] M. Prendecki,et al. New Therapeutic Targets in Antineutrophil Cytoplasm Antibody–Associated Vasculitis , 2021 .
[2] G. Riemekasten,et al. Autoantibodies against C5aR1, C3aR1, CXCR3, and CXCR4 are decreased in primary Sjogren's syndrome. , 2021, Molecular immunology.
[3] A. Kruse,et al. Autoantibodies as Endogenous Modulators of GPCR Signaling. , 2020, Trends in pharmacological sciences.
[4] Systemic Lupus Erythematosus Disease Activity Index , 2020, Definitions.
[5] M. Infantino,et al. European League against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus: the laboratory immunologist’s point of view , 2019, Annals of the Rheumatic Diseases.
[6] J. Subra,et al. Complement alternative pathway in ANCA-associated vasculitis: Two decades from bench to bedside. , 2019, Autoimmunity reviews.
[7] Yichun Hu,et al. Measuring Circulating Complement Activation Products in Myeloperoxidase– and Proteinase 3–Antineutrophil Cytoplasmic Antibody–Associated Vasculitis , 2019, Arthritis & rheumatology.
[8] Josef Spidlen,et al. Automated optimized parameters for T-distributed stochastic neighbor embedding improve visualization and analysis of large datasets , 2019, Nature Communications.
[9] D. Gladman,et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus , 2019, Arthritis & rheumatology.
[10] Robert B. Russell,et al. Illuminating the Onco-GPCRome: Novel G protein–coupled receptor-driven oncocrine networks and targets for cancer immunotherapy , 2019, The Journal of Biological Chemistry.
[11] B. Engelhardt,et al. GPCR-specific autoantibody signatures are associated with physiological and pathological immune homeostasis , 2018, Nature Communications.
[12] V. Tesar,et al. Avacopan in the treatment of ANCA-associated vasculitis , 2018, Expert opinion on investigational drugs.
[13] G. Riemekasten,et al. Autoantibodies in Serum of Systemic Scleroderma Patients: Peptide-Based Epitope Mapping Indicates Increased Binding to Cytoplasmic Domains of CXCR3 , 2018, Front. Immunol..
[14] Min Chen,et al. Plasma complement factor H is associated with disease activity of patients with ANCA-associated vasculitis , 2015, Arthritis Research & Therapy.
[15] T. Schall,et al. C5a receptor (CD88) blockade protects against MPO-ANCA GN. , 2014, Journal of the American Society of Nephrology : JASN.
[16] Min Chen,et al. Alternative complement pathway activation products in urine and kidneys of patients with ANCA-associated GN. , 2013, Clinical journal of the American Society of Nephrology : CJASN.
[17] P. Merkel,et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. , 2013, Arthritis and rheumatism.
[18] F. Luft,et al. C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. , 2009, Journal of the American Society of Nephrology : JASN.
[19] David Steven Scott,et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3) , 2008, Annals of the rheumatic diseases.
[20] L. Pasquier,et al. Orphanet Journal of Rare Diseases , 2006 .
[21] D. Gladman,et al. Systemic lupus erythematosus disease activity index 2000. , 2002, The Journal of rheumatology.
[22] C. Gordon,et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. , 1997, Arthritis and rheumatism.